ASRT

Assertio Therapeutics Inc

ASRT, USA

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

https://www.assertiotx.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ASRT
stock
ASRT

Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet Nasdaq

Read more →
ASRT
stock
ASRT

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year? Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$37.4375

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

10.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

3.58 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-9.64 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.02

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 32.04% of the total shares of Assertio Therapeutics Inc

1.

Nantahala Capital Management, LLC

(9.1543%)

since

2025/06/30

2.

Vanguard Group Inc

(4.5555%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.9767%)

since

2025/07/31

4.

Renaissance Technologies Corp

(2.9324%)

since

2025/06/30

5.

BlackRock Inc

(1.4284%)

since

2025/06/30

6.

Geode Capital Management, LLC

(1.0613%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9334%)

since

2025/07/31

8.

CM Management, LLC

(0.7527%)

since

2025/06/30

9.

Millennium Management LLC

(0.7217%)

since

2025/06/30

10.

Fidelity Extended Market Index

(0.5323%)

since

2025/07/31

11.

AQR Capital Management LLC

(0.4685%)

since

2025/06/30

12.

Morgan Stanley - Brokerage Accounts

(0.4556%)

since

2025/06/30

13.

Two Sigma Investments LLC

(0.4524%)

since

2025/06/30

14.

Two Sigma Advisers, LLC

(0.4494%)

since

2025/06/30

15.

State Street Corp

(0.3813%)

since

2025/06/30

16.

Perritt Capital Management Inc.

(0.3744%)

since

2025/06/30

17.

UBS Group AG

(0.3473%)

since

2025/06/30

18.

TSP Capital Management Group/LLC

(0.3293%)

since

2025/06/30

19.

Citadel Advisors Llc

(0.3001%)

since

2025/06/30

20.

Amvescap Plc.

(0.2813%)

since

2025/06/30

21.

Perritt MicroCap Opportunities Investor

(0.2767%)

since

2025/06/30

22.

Invesco RAFI US 1500 Small-Mid ETF

(0.2753%)

since

2025/08/29

23.

Vifag 2002 SICAV

(0.2635%)

since

2025/07/31

24.

Northern Trust Corp

(0.2361%)

since

2025/06/30

25.

EA Bridgeway Omni Small-Cap Value ETF

(0.2331%)

since

2025/08/29

26.

Bridgeway Capital Management, LLC

(0.2321%)

since

2025/06/30

27.

Empowered Funds, LLC

(0.2321%)

since

2025/06/30

28.

Extended Equity Market Fund K

(0.217%)

since

2025/06/30

29.

Fidelity Total Market Index

(0.1785%)

since

2025/07/31

30.

Fidelity Series Total Market Index

(0.1341%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - L

(0.1263%)

since

2025/06/30

32.

Northern Trust Extended Eq Market Idx

(0.1263%)

since

2025/06/30

33.

Spartan Extended Market Index Pool F

(0.1148%)

since

2025/07/31

34.

NT Ext Equity Mkt Idx Fd - NL

(0.0957%)

since

2025/06/30

35.

Empiria Max Return global V

(0.0908%)

since

2025/06/30

36.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0743%)

since

2025/06/30

37.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0641%)

since

2025/07/31

38.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0641%)

since

2024/12/31

39.

Vanguard Balanced Index Inv

(0.0588%)

since

2025/07/31

40.

Spartan Total Market Index Pool G

(0.0577%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.065

Latest Release

Date

2025-09-30

EPS Actual

0.18

EPS Estimate

-0.09

EPS Difference

0.27

Surprise Percent

300%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Moderate Quality(5.5)
Value
Undervalued(9)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.